Komori
Business alliance194AWOLVES HAND Co.,Ltd.Information and Communications, Services and Others

(Update on Previously Disclosed Matter) Notice Regarding the Launch of a Joint Research Consortium for Anti-Aging Research Using Animal Stem Cell Culture Supernatant in the Field of Regenerative Medicine

Gene expression in blood-derived cells was analyzed before and after administration of dog placental stem cell-conditioned medium (SC-CM) in 5 dogs. The analysis confirmed a reduction in TNF gene expression in all cases. Going forward, the consortium will serve as the basis for expanding the research subjects and scope of analysis.

Worth reading
47Recurring
Scored from 2 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

Agreements reached under this partnership

Details of the alliance
  1. 1

    Expand the research protocol to incorporate gene analysis of blood-derived cells in addition to clinical research on activity levels

  2. 2

    Conduct gene analysis involving a larger number of cases

  3. 3

    Conduct comprehensive analysis of genes other than TNF

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

Numerical targets under the alliance

Exploratory analysis involving 5 dogs. Timing of achievement: Not disclosed

Agreements reached under this partnership
ItemDetails
Details of the allianceExpand the research protocol to incorporate gene analysis of blood-derived cells in addition to clinical research on activity levels, Conduct gene analysis involving a larger number of cases, Conduct comprehensive analysis of genes other than TNF
Numerical targets under the allianceExploratory analysis involving 5 dogs. Timing of achievement: Not disclosed
Items this document does not state (21)
Name of alliance partnerAlliance partner's business activitiesAlliance partner's locationAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeType of allianceNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateImpact on Business PerformanceChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To clarify one aspect of SC-CM's mechanism of action and examine its relationship with anti-aging effects and inflammation suppression. In addition to clinical research on activity levels, the company plans to incorporate gene analysis of blood-derived cells and analyze more cases and genes other than TNF.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Update on Previously Disclosed Matter) Notice Regarding the Launch of a Joint Research Consortium for Anti-Aging Research Using Animal Stem Cell Culture Supernatant in the Field of Regenerative Medicine | WOLVES HAND Co.,Ltd. (194A) timely disclosure | Komori